Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

eResearch Posts Fast Money FINAL TRADE Technical Commentary

Accesswire October 1, 2013

Bristol-Myers Squibb to Present Range of New Hepatitis C Data at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Business Wire October 1, 2013

Bristol-Myers Squibb to Announce Results for Third Quarter 2013 on October 23

Business Wire October 1, 2013

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy® (ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma

Business Wire September 27, 2013

New Hypoglycemia and Pancreatitis Subanalyses from the Onglyza® (saxagliptin) SAVOR Cardiovascular Outcomes Trial Presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Business Wire September 26, 2013

New Phase III Data Showed Dapagliflozin Significantly Reduced HbA1c Compared to Placebo at 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with the Combination of Metformin Plus Sulfonylurea

Business Wire September 24, 2013

Bristol-Myers Squibb Announces Dividend

Business Wire September 17, 2013

PeptiDream Announces License of PeptiDream's Peptide Discovery Platform System (PDPS) Technology to Bristol-Myers Squibb and Extension of the Macrocyclic Peptide Drug Discovery Alliance Between the Companies

Business Wire September 17, 2013

INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab

Globe Newswire September 17, 2013

Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer

Business Wire September 12, 2013

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference

Business Wire September 4, 2013

Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease

Business Wire September 3, 2013

Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial

Business Wire September 2, 2013

New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon

Business Wire August 31, 2013

Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference

Business Wire August 29, 2013

CDR recommends self-injectable subcutaneous formulation of first non-anti-TNF biologic treatment available in both intravenous and subcutaneous formulations to be reimbursed for Canadians with moderately to severely active RA

Canada NewsWire August 12, 2013

The Straight Truth, Investing in CHTR, GM, BMY and ETN

Marketwired August 6, 2013

Before the Crowd, How We Found BMY, AAPL, XOM and RAD

Marketwired July 30, 2013

Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship

Business Wire July 29, 2013

The Reason It Trades, What's Moving WLT, KEY and BMY

Marketwired July 26, 2013